In a preclinical study (Sugawara et al., 2021), the researchers discovered that the coadministration of intratumoral G47Δ and systemic anti-CTLA-4 antibody effectively mobilized effector T cells into the tumor, concurrently reducing regulatory T cells. This evidence concerns the gene CTLA4 and neoplasm.